Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity

OMERACT 2018 Psoriatic Arthritis workshop report

Alí Duarte-García, Ying Ying Leung, Laura C Coates, Dorcas Beaton, Robin Christensen, Ethan T Craig, Maarten de Wit, Lihi Eder, Lara Fallon, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Richard Holland, Chris Lindsay, Lara Maxwell, Philip Mease, Ana Maria Orbai, Bev Shea, Vibeke Strand, Douglas J Veale & 2 others William Tillett, Alexis Ogdie

Research output: Contribution to journalArticle

2 Citations (Scopus)
6 Downloads (Pure)

Abstract

OBJECTIVE: The psoriatic arthritis (PsA) core domain set for randomized controlled trials (RCTs) and longitudinal observational studies (LOS) has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting approaches to seek endorsement of the 66/68-swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set.

METHODS: Using the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, longitudinal construct validity, sensitivity in clinical trials and thresholds of meaning). A protocol was designed to assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a "Summary of Measurement Properties Table" developed by OMERACT. OMERACT members discussed and voted on whether the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome measurement instrument for the PsA Core Outcome Measurement Set.

RESULTS: OMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis component of the MSK disease activity domain: Among patient research partners, 100% voted for a "green" endorsement, whereas among the group of "other stakeholders", 85% voted for a "green" endorsement.

CONCLUSION: The SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT Filter 2.1 and the first instrument fully endorsed within the PsA Core Outcome Measurement Set.

Original languageEnglish
JournalThe Journal of Rheumatology
Early online date15 Feb 2019
DOIs
Publication statusE-pub ahead of print - 15 Feb 2019

Cite this

Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity : OMERACT 2018 Psoriatic Arthritis workshop report. / Duarte-García, Alí; Leung, Ying Ying; Coates, Laura C; Beaton, Dorcas; Christensen, Robin; Craig, Ethan T; de Wit, Maarten; Eder, Lihi; Fallon, Lara; FitzGerald, Oliver; Gladman, Dafna D; Goel, Niti; Holland, Richard; Lindsay, Chris; Maxwell, Lara; Mease, Philip; Orbai, Ana Maria; Shea, Bev; Strand, Vibeke; Veale, Douglas J; Tillett, William; Ogdie, Alexis.

In: The Journal of Rheumatology, 15.02.2019.

Research output: Contribution to journalArticle

Duarte-García, A, Leung, YY, Coates, LC, Beaton, D, Christensen, R, Craig, ET, de Wit, M, Eder, L, Fallon, L, FitzGerald, O, Gladman, DD, Goel, N, Holland, R, Lindsay, C, Maxwell, L, Mease, P, Orbai, AM, Shea, B, Strand, V, Veale, DJ, Tillett, W & Ogdie, A 2019, 'Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report', The Journal of Rheumatology. https://doi.org/10.3899/jrheum.181089
Duarte-García, Alí ; Leung, Ying Ying ; Coates, Laura C ; Beaton, Dorcas ; Christensen, Robin ; Craig, Ethan T ; de Wit, Maarten ; Eder, Lihi ; Fallon, Lara ; FitzGerald, Oliver ; Gladman, Dafna D ; Goel, Niti ; Holland, Richard ; Lindsay, Chris ; Maxwell, Lara ; Mease, Philip ; Orbai, Ana Maria ; Shea, Bev ; Strand, Vibeke ; Veale, Douglas J ; Tillett, William ; Ogdie, Alexis. / Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity : OMERACT 2018 Psoriatic Arthritis workshop report. In: The Journal of Rheumatology. 2019.
@article{4e13bb0b05ff4b84958990949fe20da9,
title = "Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report",
abstract = "OBJECTIVE: The psoriatic arthritis (PsA) core domain set for randomized controlled trials (RCTs) and longitudinal observational studies (LOS) has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting approaches to seek endorsement of the 66/68-swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set.METHODS: Using the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, longitudinal construct validity, sensitivity in clinical trials and thresholds of meaning). A protocol was designed to assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a {"}Summary of Measurement Properties Table{"} developed by OMERACT. OMERACT members discussed and voted on whether the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome measurement instrument for the PsA Core Outcome Measurement Set.RESULTS: OMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis component of the MSK disease activity domain: Among patient research partners, 100{\%} voted for a {"}green{"} endorsement, whereas among the group of {"}other stakeholders{"}, 85{\%} voted for a {"}green{"} endorsement.CONCLUSION: The SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT Filter 2.1 and the first instrument fully endorsed within the PsA Core Outcome Measurement Set.",
author = "Al{\'i} Duarte-Garc{\'i}a and Leung, {Ying Ying} and Coates, {Laura C} and Dorcas Beaton and Robin Christensen and Craig, {Ethan T} and {de Wit}, Maarten and Lihi Eder and Lara Fallon and Oliver FitzGerald and Gladman, {Dafna D} and Niti Goel and Richard Holland and Chris Lindsay and Lara Maxwell and Philip Mease and Orbai, {Ana Maria} and Bev Shea and Vibeke Strand and Veale, {Douglas J} and William Tillett and Alexis Ogdie",
year = "2019",
month = "2",
day = "15",
doi = "10.3899/jrheum.181089",
language = "English",
journal = "The Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity

T2 - OMERACT 2018 Psoriatic Arthritis workshop report

AU - Duarte-García, Alí

AU - Leung, Ying Ying

AU - Coates, Laura C

AU - Beaton, Dorcas

AU - Christensen, Robin

AU - Craig, Ethan T

AU - de Wit, Maarten

AU - Eder, Lihi

AU - Fallon, Lara

AU - FitzGerald, Oliver

AU - Gladman, Dafna D

AU - Goel, Niti

AU - Holland, Richard

AU - Lindsay, Chris

AU - Maxwell, Lara

AU - Mease, Philip

AU - Orbai, Ana Maria

AU - Shea, Bev

AU - Strand, Vibeke

AU - Veale, Douglas J

AU - Tillett, William

AU - Ogdie, Alexis

PY - 2019/2/15

Y1 - 2019/2/15

N2 - OBJECTIVE: The psoriatic arthritis (PsA) core domain set for randomized controlled trials (RCTs) and longitudinal observational studies (LOS) has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting approaches to seek endorsement of the 66/68-swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set.METHODS: Using the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, longitudinal construct validity, sensitivity in clinical trials and thresholds of meaning). A protocol was designed to assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a "Summary of Measurement Properties Table" developed by OMERACT. OMERACT members discussed and voted on whether the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome measurement instrument for the PsA Core Outcome Measurement Set.RESULTS: OMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis component of the MSK disease activity domain: Among patient research partners, 100% voted for a "green" endorsement, whereas among the group of "other stakeholders", 85% voted for a "green" endorsement.CONCLUSION: The SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT Filter 2.1 and the first instrument fully endorsed within the PsA Core Outcome Measurement Set.

AB - OBJECTIVE: The psoriatic arthritis (PsA) core domain set for randomized controlled trials (RCTs) and longitudinal observational studies (LOS) has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting approaches to seek endorsement of the 66/68-swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set.METHODS: Using the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, longitudinal construct validity, sensitivity in clinical trials and thresholds of meaning). A protocol was designed to assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a "Summary of Measurement Properties Table" developed by OMERACT. OMERACT members discussed and voted on whether the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome measurement instrument for the PsA Core Outcome Measurement Set.RESULTS: OMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis component of the MSK disease activity domain: Among patient research partners, 100% voted for a "green" endorsement, whereas among the group of "other stakeholders", 85% voted for a "green" endorsement.CONCLUSION: The SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT Filter 2.1 and the first instrument fully endorsed within the PsA Core Outcome Measurement Set.

U2 - 10.3899/jrheum.181089

DO - 10.3899/jrheum.181089

M3 - Article

JO - The Journal of Rheumatology

JF - The Journal of Rheumatology

SN - 0315-162X

ER -